Skip to main content
. Author manuscript; available in PMC: 2022 Aug 4.
Published in final edited form as: AIDS Rev. 2022 Mar 1;24(1):41–49. doi: 10.24875/AIDSRev.22000001

Table 1.

Oral antivirals against SARS-CoV-2

Drug Viral target Chemistry Mechanism of action Comments
Molnupiravir RdRp Cytidine analog Mutagenesis Reduce hospitalizations and deaths by 30% in outpatients. Potential teratogenicity
Nirmatrelvir Mpro Small molecule Protease inhibitor Reduce hospitalizations and deaths by 89% in outpatients. Potential for drug interactions due to ritonavir boosting.
GS-621763 (oral remdesivir) RdRp Adenosine analog Chain terminator On clinical development
AT-527 RdRp Guanosine analog Chain terminator On clinical development
GC-376 Mpro Small molecule Protease inhibitor On clinical development
PBI-0451 Mpro Small molecule Protease inhibitor On clinical development

RdRp: RNA-dependent RNA polymerase; Mpro: major protease.